Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652156 | 0.86 | SSTR4 (0.49) | CKS1BSKP1SKP2IRAK4TP53 | |
| SCHEMBL1345454 | 0.83 | JAK2 (0.55) | LRRK2PIK3CAMTORCKS1BSKP1 | |
| SCHEMBL19658643 | 0.83 | CKS1B (0.50) | PIK3CAMTORCKS1BSKP1SKP2 | |
| SCHEMBL19658659 | 0.82 | CKS1B (0.49) | PIK3CAMTORCKS1BSKP1SKP2 | |
| SCHEMBL24962329 | 0.81 | HRH4 (0.44) | TP53CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL19658461 | 0.80 | MEN1 (0.59) | CKS1BSKP1SKP2 | |
| SCHEMBL28982919 | 0.78 | ACACB (0.48) | CKS1BSKP1SKP2SMPD3SSTR4 | |
| SCHEMBL17753020 | 0.78 | IDH1 (0.39) | IRAK4TP53CHRM5CHRM1CHRM3 | |
| SCHEMBL19658459 | 0.77 | JAK2 (0.42) | TP53CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL19658395 | 0.77 | KDM4E (0.51) | LRRK2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | LRRK2 416/4885PIK3CA 3080/4885MTOR 1667/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | LRRK2 416/4885PIK3CA 3080/4885MTOR 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.